Status:

ACTIVE_NOT_RECRUITING

Biomarkers of Intestinal Fibrosis in Small Bowel Crohn's Disease

Lead Sponsor:

Children's Hospital Medical Center, Cincinnati

Collaborating Sponsors:

The Leona M. and Harry B. Helmsley Charitable Trust

Conditions:

Crohn Disease

Eligibility:

All Genders

8-70 years

Brief Summary

This research study will evaluate if specific blood, stool and MRI tests can tell the difference between bowel wall inflammation without scarring and bowel wall inflammation with scarring that can cau...

Detailed Description

This multi-center study will test the accuracy of individual and combined MRI and blood-based diagnostic tools in both children and adults with small bowel CD. We will determine the accuracy of a comp...

Eligibility Criteria

Inclusion

  • Aim 1 (CD participants)
  • Aged 8-70 years
  • Undergoing first surgical distal (ileal) small bowel resection for structuring (B2 phenotype) Crohn's disease as determined by CTE or MRE or ileocolonoscopy
  • English speaking
  • Aim 2 (CD participants)
  • Age 8 to 70 years
  • Uncomplicated inflammatory small bowel CD based on clinical CTE or MRE or ileocolonoscopy performed within 6 months prior to enrollment (CD participants only)
  • English speaking
  • Aim 2 (Control participants)
  • Age 8 to 70 years
  • English speaking

Exclusion

  • Aim1 (CD participants)
  • B1 or B3 (i.e., fistula, abscess, phlegmon/inflammatory mass) CD phenotype
  • Prior small bowel surgery, including but not limited to surgical resection, stricturoplasty, or endoscopic treatment of a small bowel stricture
  • Anything to eat or drink within 4 hours of study visit (participants may take their required medications with a little water)
  • Known pregnancy (Note: Institutional policies/procedures will be followed for pregnancy screening)
  • Contraindication for MRI (e.g., surgical implant, claustrophobia). Note: To be determined based on local procedures.
  • Aim 2 (CD participants)
  • Stenotic ileocecal valve at colonoscopy
  • Prior small bowel surgery, including but not limited to surgical resection, stricturoplasty, or endoscopic treatment of a small bowel stricture
  • Anything to eat or drink within 4 hours of study visit (participants may take their required medications with a little water)
  • Known pregnancy (Note: Institutional policies/procedures will be followed for pregnancy screening)
  • Contraindication for MRI (e.g., surgical implant, claustrophobia). Note: To be determined based on local procedures.
  • Aim 2 (Control participants)
  • Any known gastrointestinal tract disease
  • Any known inflammatory/autoimmune disease involving another organ system (e.g., rheumatoid arthritis, scleroderma, multiple sclerosis).
  • Fecal calprotectin level of ˃100 mcg.gm will be excluded from further analysis and replaced.

Key Trial Info

Start Date :

November 1 2019

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 1 2026

Estimated Enrollment :

232 Patients enrolled

Trial Details

Trial ID

NCT04088773

Start Date

November 1 2019

End Date

June 1 2026

Last Update

June 13 2025

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Emory/Children's Healthcare of Atlanta

Atlanta, Georgia, United States, 30322

2

Michigan Medicine

Ann Arbor, Michigan, United States, 48109

3

Mayo Clinic

Rochester, Minnesota, United States, 55905

4

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229